Login to Your Account



Actelion Must Pay $547M in Dispute with Asahi Kasei

By Nuala Moran


Tuesday, May 3, 2011
LONDON – The pressure on Actelion Ltd. is intensifying after a U.S. jury said the company should pay out $547 million in its license dispute with Asahi Kasei Pharma Corp of Tokyo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription